Search

Displaying results 2011 - 2020 of 10000 in total
  1. Drug

    Ferric carboxymaltose

    go.drugbank.com/drugs/DB08917
    ApprovedInvestigational

    Ferric carboxymaltose is an iron replacement product and, chemically, an iron-carbohydrate complex. It was FDA approved on July 25, 2013.

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Regdanvimab

    go.drugbank.com/drugs/DB16405
    ApprovedWithdrawn

    [A235830,A241995] It received its first full approval in South Korea in September 2021,[A241995] followed by the EU in November 2021.[L39130] … Trials investigating the use of regdanvimab as a therapeutic candidate for the treatment of COVID-19 began in mid-2020.

  3. Drug

    Eftrenonacog alfa

    go.drugbank.com/drugs/DB11608
    Approved

    It is comprised of a single molecule of human factor IX (FIX) covalently linked to the constant region (Fc) domain of human IgG1 via recombinant DNA technology in a human embryonic kidney cell line (HEK293H … It was first approved by the FDA in March 2014 and later approved by the EMA in May 2016.

    Synonyms: Recombinant human coagulation factor IX, FC Fusion protein, Coagulation factor IX recombinant immunoglubulin g1 fusion proteinProducts: ALPROLIX® 250 UI
  4. Drug

    Sotrovimab

    go.drugbank.com/drugs/DB16355
    ApprovedInvestigational

    found to reduce the risk of death or hospitalization in high-risk adults with COVID-19 in the outpatient setting. … [L41369] Sotrovimab was granted marketing authorization in the European Union in December 2021 under the brand name Xevudy.[L39625,L39620]

  5. Drug

    Efonidipine

    go.drugbank.com/drugs/DB09235
    Investigational

    The drug has been shown to block T-type in addition to L-type calcium channels [A7844, A32001]. It has also been studied in atherosclerosis and acute renal failure [A32001]. … This drug is also known as NZ-105, and several studies have been done on its pharmacokinetics in animals [L1456].

  6. Drug

    Bordetella pertussis fimbriae 2/3 antigen

    go.drugbank.com/drugs/DB10790
    ApprovedInvestigational

    Bordetella pertussis fimbriae 2/3 antigen is a vaccine for the prophylaxis of the disease caused by Bordetella pertussis which is a a Gram-negative coccobacillus that expresses two serologically distinct

    Mixtures: Repevax Injektionssuspension in einer Fertigspritze, Covaxis Injektionssuspension in einer Fertigspritze
  7. Drug

    Genistein

    go.drugbank.com/drugs/DB01645
    Investigational

    Experimentally, it has been shown to induce G2 phase arrest in human and murine cell lines. Additionally, genistein has antihelmintic activity. … It has been determined to be the active ingredient in <I>Felmingia vestita</I>, which is a plant traditionally used against worms.

    Mixtures: OSMEGA 600 MG/400 IU/25 MG EFERVESAN TABLET, 30 ADET, CALCIDAY G 1200 MG/800 IU/50 MG EFERVESAN TABLET, 45 ADETCategories: Compounds used in a research, industrial, or household setting
  8. Drug

    Nitazoxanide

    go.drugbank.com/drugs/DB00507
    ApprovedInvestigationalVet approved

    Nitazoxanide is a first-line, standard treatment for illness caused by C. parvum or G. lamblia infection in healthy (not immunosuppressed) adults and children and may also be considered in the treatment … This drug is effective in the treatment of gastrointestinal infections including Cryptosporidium parvum or Giardia lamblia in healthy subjects. It is generally well tolerated.

    Products: N/a
  9. Drug

    Infigratinib

    go.drugbank.com/drugs/DB11886
    ApprovedInvestigationalWithdrawn

    difficulties and commercial infeasibility in continuing drug distribution. … By inhibiting the FGFR pathway, which is often aberrated in cancers such as cholangiocarcinoma, infigratinib suppresses tumour growth.

  10. Drug

    Vorapaxar

    go.drugbank.com/drugs/DB09030
    Approved

    Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history … of myocardial infarction (MI) or with peripheral arterial disease (PAD).

    Synonyms: Carbamic acid, N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(E)-2-[5-(3-fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]-, ethyl ester, Ethyl N-[(3R,3aS,4S,4aR,7R,8aR,9aR)-4-[(E)-2-[5-(3-fluorophenyl)-2-pyridyl]vinyl]-3-methyl-1-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-3H-benzo[f]isobenzofuran-7-yl]carbamate